MMMichał Mazurkiewicz

Michał Mazurkiewicz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michał Mazurkiewicz has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neurosarcoidosis: symptoms, diagnosis, and treatment – current state of knowledge

    by Michał Andrzej Mazurkiewicz, Iwona Sylwia Skrzypczak

    Neurosarcoidosis is an inflammatory disease of unknown aetiology, characterised by the presence of non-caseating granulomas within the nervous system. Its prevalence in patients diagnosed with sarcoidosis is estimated to be approximately 10%. The clinical presentation is ambiguous, with symptoms that may manifest acutely or progress gradually over time. Many of these symptoms mimic those of other diseases, making neurosarcoidosis a diagnostic challenge. No sufficiently sensitive or specific biomarkers are available to enable an accurate diagnosis. A range of diagnostic tests must be performed to exclude other conditions. Histopathological confirmation via biopsy is necessary to make a definitive diagnosis, which is not always possible due to the location of lesions and the potential risk of complications associated with performing a biopsy. Once a diagnosis is established, regular follow-up examinations are necessary to monitor disease activity and assess the progression of changes. The optimal treatment strategy depends on the patient’s current clinical status and the potential risk of side effects. Three main lines of treatment for neurosarcoidosis have been described. Treatment selection should also take into account the ability of medications to cross the blood–brain barrier. Treatment response, severity of the disease at the time of diagnosis, and lesion location within the nervous system all influence the prognosis. With appropriate treatment, the majority of patients achieve either complete or partial remission. Therefore, neurosarcoidosis requires multidisciplinary specialist care and a comprehensive approach to each patient.

  • Open Access

    Gut microbiota in adults with cystic fibrosis: Implications for the severity of the CFTR gene mutation and nutritional status

    by Magdalena Durda-Masny, Joanna Goździk-Spychalska, Katarzyna Morańska, Natalia Pawłowska, Michał Mazurkiewicz, Iwona Skrzypczak, Szczepan Cofta, Anita Szwed


  • Open Access

    C-Reactive Protein and Albumin Levels as Useful Tools for Predicting In-Hospital Outcomes in Polish Nonagenarians

    by Michal Mazurkiewicz, Wojciech Lizurej, Lukasz Mazurkiewicz, Arkadiusz Majewski, Slawomir Tobis, Maciej Cymerys

    Purpose: The admissions of nonagenarians to internal medicine wards are rising. The aim of this study was to analyse the causes of ward admission and blood and renal parameters as potential mortality predictors in this age group. Patients and Methods: Out of 1140 patients, 111 nonagenarians aged 90+ admitted to the Internal Medicine Ward in one general hospital in Poznan in 2019 were studied. Medical records of these patients were analysed to find factors attributable to the hospitalisation. Results: The leading causes of admission were infections and cardiovascular diseases, and the main causes of death were cardiovascular diseases. Elevated C-reactive protein (CRP) level was a statistically significant death predictor. Equally, decreased albumin level was found to be a mortality predictor. No such relationships were obtained for haematological or renal parameters. Conclusion: Our study uniquely analysed a relatively large group of hospitalised nonagenarians and identified those who need particular attention in the ward by identifying those with the highest risk of death. CRP and albumin levels may serve as useful indicators of in-hospital mortality in this age group.


  • Mascots

    by Michał Mazurkiewicz

    "Mascots" published on Dec 2021 by Edward Elgar Publishing.